Yi Ren
Yi Ren has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Chang Liu
Department of Thoracic Surgery, Shenyang Chest Hospital
4 shared publicationsGuofeng Zhang
Department of Thoracic Surgery, Shenyang Chest Hospital
4 shared publicationsSibo You
Department of Thoracic Surgery, Shenyang Chest Hospital
4 shared publicationsZhengjun Li
Department of Thoracic Surgery, Shenyang Chest Hospital
3 shared publicationsDing Li
Department of Operating Room, Shenyang Tenth People’s Hospital
2 shared publicationsSiwei Chao
Department of Thoracic Surgery, Shenyang Chest Hospital
2 shared publications
Latest Publications
- Open Access
- 15 July 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1818928
Preoperative evaluation of solitary pulmonary nodules and adenocarcinoma invasiveness using ultra-high-resolution computed tomography and multidimensional liquid biopsy: a prospective exploratory study
Background: Accurate preoperative characterization of solitary pulmonary nodules (SPNs), particularly differentiation of benign from malignant lesions and assessment of adenocarcinoma invasiveness, remains challenging based on morphological features alone. We investigated whether integrating 1024-matrix ultra-high-resolution computed tomography (UHRCT) with two liquid-biopsy signals, urinary cellular energy metabolism (CEM) and a seven tumor-associated autoantibody (7-TAAb) panel, could improve diagnostic performance in surgically treated patients with SPNs. Methods: In this single-center prospective study, consecutive adults with SPNs (≤3 cm) scheduled for video-assisted thoracoscopic surgery between January 2022 and December 2024 were enrolled (n = 183). All patients underwent preoperative UHRCT (1024×1024), urinary CEM testing, and 7-TAAb testing. A paired subgroup (n = 85) additionally underwent conventional HRCT (512×512) within 1 month before surgery. Postoperative histopathology served as the reference standard. Diagnostic performance metrics were calculated for each modality, parallel-rule combined strategies, and probability-based logistic regression models. Results: Among 183 patients, 164 (89.6%) had malignant nodules. UHRCT achieved the best single-modality discrimination (AUC, 0.831; sensitivity, 87.2%; specificity, 78.9%), outperforming CEM (AUC, 0.605) and 7-TAAbs (AUC, 0.558). Under the parallel-rule strategy, multimodal testing increased sensitivity but markedly reduced specificity (sensitivity 98.8%, specificity 9.5%). The probability-based fully integrated model achieved the highest AUC (0.946). At the Youden-index threshold of 0.816, this model yielded sensitivity of 92.7%, specificity of 84.2%, PPV of 98.1%, NPV of 57.1%, and accuracy of 91.8%. In the paired comparison (n = 85), UHRCT showed higher sensitivity (92.0% vs. 68.0%) and specificity (90.0% vs. 73.3%) than HRCT. For invasiveness assessment, positivity rates of both urinary CEM (57.6% vs. 31.6%) and 7-TAAbs (53.8% vs. 31.0%) were higher in invasive adenocarcinoma than in pre-invasive lesions. Conclusion: In surgically selected patients with SPNs, 1024-matrix UHRCT provided the strongest single-modality diagnostic information, while urinary CEM and 7-TAAbs offered complementary biological signals associated with invasive adenocarcinoma pathology. Probability-based integration provided a more balanced diagnostic framework than a simple parallel-rule strategy. Given the high prevalence of malignancy and the limited number of benign lesions, these findings should be considered exploratory and require external validation in broader outpatient and screening cohorts.
- 15 July 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1818928
Open AccessPreoperative evaluation of solitary pulmonary nodules and adenocarcinoma invasiveness using ultra-high-resolution computed tomography and multidimensional liquid biopsy: a prospective exploratory study
Background: Accurate preoperative characterization of solitary pulmonary nodules (SPNs), particularly differentiation of benign from malignant lesions and assessment of adenocarcinoma invasiveness, remains challenging based on morphological features alone. We investigated whether integrating 1024-matrix ultra-high-resolution computed tomography (UHRCT) with two liquid-biopsy signals, urinary cellular energy metabolism (CEM) and a seven tumor-associated autoantibody (7-TAAb) panel, could improve diagnostic performance in surgically treated patients with SPNs. Methods: In this single-center prospective study, consecutive adults with SPNs (≤3 cm) scheduled for video-assisted thoracoscopic surgery between January 2022 and December 2024 were enrolled (n = 183). All patients underwent preoperative UHRCT (1024×1024), urinary CEM testing, and 7-TAAb testing. A paired subgroup (n = 85) additionally underwent conventional HRCT (512×512) within 1 month before surgery. Postoperative histopathology served as the reference standard. Diagnostic performance metrics were calculated for each modality, parallel-rule combined strategies, and probability-based logistic regression models. Results: Among 183 patients, 164 (89.6%) had malignant nodules. UHRCT achieved the best single-modality discrimination (AUC, 0.831; sensitivity, 87.2%; specificity, 78.9%), outperforming CEM (AUC, 0.605) and 7-TAAbs (AUC, 0.558). Under the parallel-rule strategy, multimodal testing increased sensitivity but markedly reduced specificity (sensitivity 98.8%, specificity 9.5%). The probability-based fully integrated model achieved the highest AUC (0.946). At the Youden-index threshold of 0.816, this model yielded sensitivity of 92.7%, specificity of 84.2%, PPV of 98.1%, NPV of 57.1%, and accuracy of 91.8%. In the paired comparison (n = 85), UHRCT showed higher sensitivity (92.0% vs. 68.0%) and specificity (90.0% vs. 73.3%) than HRCT. For invasiveness assessment, positivity rates of both urinary CEM (57.6% vs. 31.6%) and 7-TAAbs (53.8% vs. 31.0%) were higher in invasive adenocarcinoma than in pre-invasive lesions. Conclusion: In surgically selected patients with SPNs, 1024-matrix UHRCT provided the strongest single-modality diagnostic information, while urinary CEM and 7-TAAbs offered complementary biological signals associated with invasive adenocarcinoma pathology. Probability-based integration provided a more balanced diagnostic framework than a simple parallel-rule strategy. Given the high prevalence of malignancy and the limited number of benign lesions, these findings should be considered exploratory and require external validation in broader outpatient and screening cohorts.
- Open Access
- 13 March 2026
- Published by Elsevier in Annals of Thoracic Surgery Short Reports
- Vol. 4 (2) , 733-736
Ultra–Minimally Invasive Medical Thoracoscopic Sympathectomy for Primary Palmar Hyperhidrosis
- 13 March 2026
- Published by Elsevier in Annals of Thoracic Surgery Short Reports
- Vol. 4 (2) , 733-736
Open AccessUltra–Minimally Invasive Medical Thoracoscopic Sympathectomy for Primary Palmar Hyperhidrosis
- Open Access
- 1 March 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-25
Recent Advances in Nanocarrier-Based Drug Delivery Systems for Lung Cancer
Lung cancer (LC) remains the leading cause of cancer-related deaths globally. Conventional therapeutic strategies, including surgery, radiotherapy, and chemotherapy, are often hampered by limitations such as poor tumor selectivity, low bioavailability, and severe systemic toxicity, which compromise treatment efficacy. Nanocarriers are colloidal formulations characterized by abundant porosity and unique physicochemical properties, such as tunable size, high specific surface area, and stimuli-responsiveness. Nanocarrier-based drug delivery systems (NDDSs) have emerged as a promising solution to enable targeted delivery, controlled drug release, and theranostics. This review discusses the advantages, limitations, and clinical translation of three major classes of nanodelivery systems for LC therapy: organic, inorganic, and inorganic–organic hybrid nanosystems. Organic systems are characterized by high biocompatibility and versatile drug-loading capacity, whereas inorganic counterparts provide distinctive optical or magnetic functionalities that enable imaging and synergistic therapy. Hybrid designs integrate both material classes to improve stability and therapeutic performance. Future research is expected to focus on optimizing inhalation strategies for deep lung deposition, developing multi-targeted biomimetic carriers, advancing theranostic platforms, and employing computational tools to accelerate nanocarrier design and clinical translation. This review aims to offer critical perspectives on the development and clinical implementation of nanomedicines for LC.
- 1 March 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-25
Open AccessRecent Advances in Nanocarrier-Based Drug Delivery Systems for Lung Cancer
Lung cancer (LC) remains the leading cause of cancer-related deaths globally. Conventional therapeutic strategies, including surgery, radiotherapy, and chemotherapy, are often hampered by limitations such as poor tumor selectivity, low bioavailability, and severe systemic toxicity, which compromise treatment efficacy. Nanocarriers are colloidal formulations characterized by abundant porosity and unique physicochemical properties, such as tunable size, high specific surface area, and stimuli-responsiveness. Nanocarrier-based drug delivery systems (NDDSs) have emerged as a promising solution to enable targeted delivery, controlled drug release, and theranostics. This review discusses the advantages, limitations, and clinical translation of three major classes of nanodelivery systems for LC therapy: organic, inorganic, and inorganic–organic hybrid nanosystems. Organic systems are characterized by high biocompatibility and versatile drug-loading capacity, whereas inorganic counterparts provide distinctive optical or magnetic functionalities that enable imaging and synergistic therapy. Hybrid designs integrate both material classes to improve stability and therapeutic performance. Future research is expected to focus on optimizing inhalation strategies for deep lung deposition, developing multi-targeted biomimetic carriers, advancing theranostic platforms, and employing computational tools to accelerate nanocarrier design and clinical translation. This review aims to offer critical perspectives on the development and clinical implementation of nanomedicines for LC.
- Open Access
- 22 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (12) , 8972-8975
Multifocal community-acquired MRSA infection: a rare case involving urinary tract, bloodstream, chest wall, and pleura
Introduction: Methicillin-resistant Staphylococcus aureus (MRSA) is a common cause of hospital- and community-acquired multidrug-resistant infections. Typical infection sites include the skin, respiratory tract, and bloodstream. This report describes a rare case of multifocal community-acquired MRSA (CA-MRSA) infection simultaneously causing urinary tract infection, bacteremia, chest wall abscess, and empyema. Case presentation: A 51-year-old man with newly diagnosed diabetes mellitus on admission was admitted with a 2-week history of right posterior chest wall pain and a mass. Imaging showed soft tissue swelling in the right chest wall and pleural effusion. Urine and blood cultures grew MRSA. The patient was treated with linezolid and levofloxacin, insulin therapy, and nutritional support, and the chest wall abscess was incised and drained. Pus culture and targeted next-generation sequencing (tNGS) confirmed MRSA infection with mecA and SCCmec antimicrobial-resistance genes. The patient recovered and had no recurrence during 2 months of follow up. Discussion: This case reveals that CA-MRSA can cause disseminated infections without obvious predisposing factors such as catheterization or trauma. Hyperglycemia and HHV-6 suggest impaired immune function. Combination antimicrobial therapy and surgical intervention were effective in the short term; however, the short follow-up period limits assessment of long-term outcomes. tNGS played a crucial role in identifying antimicrobial-resistance mechanisms. Conclusion: CA-MRSA can cause multifocal infections in immunocompromised patients. This rare case, with simultaneous urinary, bloodstream, chest wall, and pleural involvement, highlights the importance of early recognition, individualized therapy, and confirmation of resistance using tNGS. The outcome demonstrates the short-term effectiveness of this combined approach.
- 22 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (12) , 8972-8975
Open AccessMultifocal community-acquired MRSA infection: a rare case involving urinary tract, bloodstream, chest wall, and pleura
Introduction: Methicillin-resistant Staphylococcus aureus (MRSA) is a common cause of hospital- and community-acquired multidrug-resistant infections. Typical infection sites include the skin, respiratory tract, and bloodstream. This report describes a rare case of multifocal community-acquired MRSA (CA-MRSA) infection simultaneously causing urinary tract infection, bacteremia, chest wall abscess, and empyema. Case presentation: A 51-year-old man with newly diagnosed diabetes mellitus on admission was admitted with a 2-week history of right posterior chest wall pain and a mass. Imaging showed soft tissue swelling in the right chest wall and pleural effusion. Urine and blood cultures grew MRSA. The patient was treated with linezolid and levofloxacin, insulin therapy, and nutritional support, and the chest wall abscess was incised and drained. Pus culture and targeted next-generation sequencing (tNGS) confirmed MRSA infection with mecA and SCCmec antimicrobial-resistance genes. The patient recovered and had no recurrence during 2 months of follow up. Discussion: This case reveals that CA-MRSA can cause disseminated infections without obvious predisposing factors such as catheterization or trauma. Hyperglycemia and HHV-6 suggest impaired immune function. Combination antimicrobial therapy and surgical intervention were effective in the short term; however, the short follow-up period limits assessment of long-term outcomes. tNGS played a crucial role in identifying antimicrobial-resistance mechanisms. Conclusion: CA-MRSA can cause multifocal infections in immunocompromised patients. This rare case, with simultaneous urinary, bloodstream, chest wall, and pleural involvement, highlights the importance of early recognition, individualized therapy, and confirmation of resistance using tNGS. The outcome demonstrates the short-term effectiveness of this combined approach.
- Open Access
- 18 October 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1260759
Immunohistochemistry combined with NGS to assist the differential diagnosis of multiple primary lung cancer with lymph node metastasis: a case report
In recent years, the incidence of synchronous multiple primary lung cancers (MPLCs) has gradually increased. Surgery is the preferred treatment for these patients. There are great differences in the driving genes between individual tumors in patients with MPLC, and tumors with targeted mutations do not represent other tumors, which challenges the selection of targeted therapies for patients with MPLC. Driving mutations in each lesion after surgery are crucial for establishing accurate pathological staging and subsequent treatment strategies. There are some mutated genes in the lymph nodes of postoperative metastatic MPLCs, and the tumor cell count/DNA concentration is low, which limits the next-generation sequencing (NGS) detection effect. A combination with immunohistochemistry to determine the source of metastasis may be a better choice. This study reports a rare case of lung cancer with double primary adenocarcinomas of the lung combined with 10 groups of lymph node metastases. The source of metastasis was identified using immunohistochemistry combined with NGS to guide postoperative adjuvant treatment. We hope that this case report can provide new ideas for the identification of MPLCs and assist in their diagnosis and individualized treatment. In addition, the combination specific immunohistochemistry and NGS seems to be an effective identification method. This approach can provide clinical benefits; however, this still requires further exploration through studies with large sample sizes.
- 18 October 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1260759
Open AccessImmunohistochemistry combined with NGS to assist the differential diagnosis of multiple primary lung cancer with lymph node metastasis: a case report
In recent years, the incidence of synchronous multiple primary lung cancers (MPLCs) has gradually increased. Surgery is the preferred treatment for these patients. There are great differences in the driving genes between individual tumors in patients with MPLC, and tumors with targeted mutations do not represent other tumors, which challenges the selection of targeted therapies for patients with MPLC. Driving mutations in each lesion after surgery are crucial for establishing accurate pathological staging and subsequent treatment strategies. There are some mutated genes in the lymph nodes of postoperative metastatic MPLCs, and the tumor cell count/DNA concentration is low, which limits the next-generation sequencing (NGS) detection effect. A combination with immunohistochemistry to determine the source of metastasis may be a better choice. This study reports a rare case of lung cancer with double primary adenocarcinomas of the lung combined with 10 groups of lymph node metastases. The source of metastasis was identified using immunohistochemistry combined with NGS to guide postoperative adjuvant treatment. We hope that this case report can provide new ideas for the identification of MPLCs and assist in their diagnosis and individualized treatment. In addition, the combination specific immunohistochemistry and NGS seems to be an effective identification method. This approach can provide clinical benefits; however, this still requires further exploration through studies with large sample sizes.
- Open Access
- Vol. 13
Application and advantages of intrathoracic paravertebral block in uniportal video-assisted thoracoscopic surgery
Uniportal video-assisted thoracoscopic surgery (VATS) is widely used as a minimally invasive approach for pulmonary diseases. Although this technique reduces postoperative pain, acute postoperative pain remains clinically significant. This study aimed to evaluate the feasibility and advantages of thoracoscopic paravertebral block. This single-center prospective randomized comparative study included 228 consecutive patients who underwent uniportal VATS at our institution between August 2022 and June 2024. Patients were randomly assigned to Group A (122 patients; intraoperative thoracoscopic direct-vision transthoracic paravertebral block) or Group B (106 patients; preoperative ultrasound-guided thoracic paravertebral block). Perioperative data, postoperative pain scores, opioid rescue analgesic use, and postoperative complications were analyzed. Repeated-measures analysis of variance was used to assess differences in postoperative pain scores over time between the two groups. A total of 228 patients underwent uniportal VATS pulmonary resection. No significant differences were observed between the two groups in terms of age, sex, pulmonary function, arterial blood gas analysis, surgical side, incision location, nodule size, nodule position, operative time, blood loss, drainage duration, length of hospital stay, tumor stage, or postoperative complications (P > 0.05). Postoperative complications were less frequent in Group A than in Group B. No intraoperative or 30-day postoperative mortality occurred in either group. Repeated-measures ANOVA showed significant effects of group (F = 774.002, P < 0.001), time (F = 520.972, P < 0.001), and group×time interaction (F = 4.983, P = 0.001) on VAS scores. These findings indicate that thoracoscopic paravertebral block is safe and effective. Compared with ultrasound-guided approaches, it was associated with lower postoperative pain scores and reduced rescue tramadol requirements. Further validation through prospective randomized controlled trials is required.
- Vol. 13
Open AccessApplication and advantages of intrathoracic paravertebral block in uniportal video-assisted thoracoscopic surgery
Uniportal video-assisted thoracoscopic surgery (VATS) is widely used as a minimally invasive approach for pulmonary diseases. Although this technique reduces postoperative pain, acute postoperative pain remains clinically significant. This study aimed to evaluate the feasibility and advantages of thoracoscopic paravertebral block. This single-center prospective randomized comparative study included 228 consecutive patients who underwent uniportal VATS at our institution between August 2022 and June 2024. Patients were randomly assigned to Group A (122 patients; intraoperative thoracoscopic direct-vision transthoracic paravertebral block) or Group B (106 patients; preoperative ultrasound-guided thoracic paravertebral block). Perioperative data, postoperative pain scores, opioid rescue analgesic use, and postoperative complications were analyzed. Repeated-measures analysis of variance was used to assess differences in postoperative pain scores over time between the two groups. A total of 228 patients underwent uniportal VATS pulmonary resection. No significant differences were observed between the two groups in terms of age, sex, pulmonary function, arterial blood gas analysis, surgical side, incision location, nodule size, nodule position, operative time, blood loss, drainage duration, length of hospital stay, tumor stage, or postoperative complications (P > 0.05). Postoperative complications were less frequent in Group A than in Group B. No intraoperative or 30-day postoperative mortality occurred in either group. Repeated-measures ANOVA showed significant effects of group (F = 774.002, P < 0.001), time (F = 520.972, P < 0.001), and group×time interaction (F = 4.983, P = 0.001) on VAS scores. These findings indicate that thoracoscopic paravertebral block is safe and effective. Compared with ultrasound-guided approaches, it was associated with lower postoperative pain scores and reduced rescue tramadol requirements. Further validation through prospective randomized controlled trials is required.